Valuation: H&R GmbH & Co KgaA

Market Cap 226M 258M 210M 193M 365M 24.7B 372M 2.5B 980M 12.13B 969M 948M 41.88B P/E 2026 *
38.7x
P/E 2027 * 28.5x
Enterprise Value 382M 436M 354M 326M 616M 41.73B 628M 4.22B 1.66B 20.49B 1.64B 1.6B 70.77B EV / Sales 2026 *
0.3x
EV / Sales 2027 * 0.29x
Free-Float
21.97%
Yield 2026 *
0.82%
Yield 2027 * 0.82%
05-15 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-28 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
11-14 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
25-08-24 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
25-08-15 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
25-05-13 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-16 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
25-04-08 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-03-26 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
25-03-26 H&R GmbH & Co. KGaA Announces Postponement of the Publication of the Consolidated Financial Statements and the Annual Report 2024 CI
Manager TitleAgeSince
Chief Executive Officer 61 2015-12-31
Investor Relations Contact - 2005-12-31
Director TitleAgeSince
Chairman 62 2012-04-16
Director/Board Member 71 2011-04-30
Director/Board Member 69 2011-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 255M
+1.40%-1.97%+11.03%+34.65% 126B
+9.92%+1.27%+648.59%+187.46% 44.85B
+0.57%+0.96%-5.83%-40.68% 41.71B
-2.56%-3.22%+20.15%-26.31% 31.72B
+1.97%+0.88%+32.82%+55.56% 21.8B
+3.50%+10.10%-7.49%-37.09% 18.19B
-5.08%-12.40%+331.83%+569.58% 18.14B
-0.44%-1.93%+17.74%+403.91% 17.3B
-3.36%-14.97%+57.04%+190.38% 17.29B
Average +0.59%-1.43%+122.88%+148.61% 37.5B
Weighted average by Cap. +1.52%-1.31%+114.88%+93.06%

Financials

2026 *2027 *
Net sales 1.29B 1.47B 1.2B 1.1B 2.08B 141B 2.13B 14.28B 5.6B 69.32B 5.54B 5.42B 239B 1.33B 1.52B 1.23B 1.13B 2.14B 145B 2.19B 14.68B 5.76B 71.29B 5.7B 5.57B 246B
Net income 5.85M 6.67M 5.42M 4.98M 9.43M 638M 9.61M 64.56M 25.32M 313M 25.04M 24.49M 1.08B 8M 9.12M 7.4M 6.81M 12.89M 872M 13.14M 88.26M 34.61M 428M 34.23M 33.48M 1.48B
Net Debt 156M 178M 145M 133M 252M 17.04B 257M 1.72B 676M 8.37B 668M 654M 28.89B 158M 180M 146M 135M 254M 17.22B 259M 1.74B 683M 8.46B 676M 661M 29.21B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-